21 active not recruiting. 21 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Active not recruiting 21 |
| Phase 2 | 6 | Active not recruiting 6 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 | Active not recruiting | Ruijin Hospital | 9 | 2025-03-12 | 2026-11-02 |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers NXP900 - Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer) | Phase 1 | Active not recruiting | Nuvectis Pharma, Inc. | 140 | 2023-10-26 | 2026-09-30 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers KFA115, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2022-10-26 | 2026-10-20 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®) - Pancreatic Cancer, Breast Cancer | Phase 1 | Active not recruiting | NGM Biopharmaceuticals, Inc | 130 | 2022-03-31 | 2024-10-10 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors HFB200301, Tislelizumab - Gastric Cancer, Renal Cell Carcinoma | Phase 1 | Active not recruiting | HiFiBiO Therapeutics | 72 | 2022-03-10 | 2025-11-21 |
| A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors IAG933 - Mesothelioma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 137 | 2021-10-21 | 2026-06-22 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma Pembrolizumab, IMPRINT - Malignant Pleural Mesothelioma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2021-08-10 | 2026-03-12 |
| Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma cyclophosphamide, CAR T cells - Malignant Pleural Mesothelioma (MPM) | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 14 | 2020-09-30 | 2026-10-29 |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers IOA-244, Avelumab Injection, Pemetrexed - Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult | Phase 1 | Active not recruiting | iOnctura | 210 | 2020-02-25 | 2026-07-08 |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Pembrolizumab, Autologous dendritic cells, Interleukin-2 - Mesothelioma, Malignant, PD-L1 Negative | Phase 1 | Active not recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 18 | 2019-12-12 | 2024-10-01 |
| A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Nivolumab, Pemetrexed, Cisplatin or Carboplatin - Malignant Pleural Mesothelioma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 22 | 2019-11-12 | 2026-09-11 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab - ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | NeoTX Therapeutics Ltd. | 120 | 2019-10-10 | 2025-11-28 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab - Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2018-10-04 | 2026-10-15 |
| Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma Atezolizumab, Cisplatin, Extrapleural Pneumonectomy - Biphasic Mesothelioma, Epithelioid Mesothelioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2018-07-16 | 2026-10-22 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers CK-301 (cosibelimab) - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Checkpoint Therapeutics, Inc. | 272 | 2017-09-20 | 2025-02-03 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
Showing 20 of 21. Sign in to see all of them.
Mesothelioma, Malignant (13) · Mesothelioma (9) · Melanoma (7) · Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Renal Cell (6) · Ovarian Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Esophageal Neoplasms (4) · Lung Neoplasms (4) · Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Uterine Cervical Neoplasms (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Skin Neoplasms (3)
Neoplasms by Histologic Type (21) · Neoplasms, Glandular and Epithelial (21) · Neoplasms, Mesothelial (21) · Neoplasms by Site (20) · Lung Diseases (18) · Respiratory Tract Diseases (18) · Respiratory Tract Neoplasms (18) · Thoracic Neoplasms (18) · Neoplasms (17) · Lung Neoplasms (14) · Pleural Neoplasms (13) · Mesothelioma (12) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9)
pembrolizumab (7) · Cisplatin (6) · Pemetrexed (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Platinum (4) · Cyclophosphamide (3) · Interleukin-2 (2) · Nivolumab (2) · BAY 1895344 (1) · Carboplatin (1) · Drug Therapy (1) · Gemcitabine (1) · Immunotherapy, Adoptive (1) · Imprint II (1) · Ipilimumab (1)
National Cancer Institute (NCI) (5) · Memorial Sloan Kettering Cancer Center (4) · Novartis Pharmaceuticals (2) · Checkpoint Therapeutics, Inc. (1) · HiFiBiO Therapeutics (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Medicenna Therapeutics, Inc. (1) · NGM Biopharmaceuticals, Inc (1) · NeoTX Therapeutics Ltd. (1) · Nuvectis Pharma, Inc. (1) · Ruijin Hospital (1) · TCR2 Therapeutics (1) · iOnctura (1)
United States (16) · Canada (6) · Spain (5) · Italy (4) · Australia (3) · France (3) · United Kingdom (3) · China (2) · Germany (2) · Japan (2) · South Korea (2) · Switzerland (2) · Hong Kong (1) · India (1) · Ireland (1)
Anne S Tsao (2) · Roisin O'Cearbhaill, MD (2) · Aaron S Mansfield (1) · Arash Yavari, MBBS (1) · Charles Simone, MD (1) · Gerald Falchook, MD (1) · Mamta Parikh (1) · Marianna Koczywas (1) · Massimo Guidoboni, MD (1) · Michael Lahn (1) · Michael Offin, MD (1) · Nina Merchant (1) · Tal Hetzroni Kedem (1) · Udai Banerji, Prof (1)
PMID 31386610, PMID 35045358, PMID 37501016, PMID 37589506, PMID 37848259, PMID 38321811, PMID 39089584, PMID 42855460
U10CA180888 (2), UM1CA186717 (2), 2019 (1), 2023 (1), U10CA032102 (1), U10CA180830 (1), UM1CA186686 (1), UM1CA186689 (1), UM1CA186705 (1), UM1CA186709 (1), ZIABC011078 (1)